Immune checkpoint antibodies, such as anti-CTLA4 [44] or anti-PD-1 [45], can enhance the CTL response to solid tumors by “loosening the brakes” on the immune response to cancers, which originate from self-tissues. The gene discussed is CTLA4; the disease is cancer.